Group 1 - The core point of the article is that Kangtai Medical has established a wholly-owned subsidiary, Medical Electric Precision Testing Technology Service (Qinhuangdao) Co., Ltd., with an investment of 5 million RMB to enhance its business development and competitiveness [2][3] - The subsidiary has completed the registration process and obtained a business license from the Qinhuangdao Economic and Technological Development Zone Administration [2]

康泰医学公告，公司出资人民币500万元设立全资子公司医电精测技术服务（秦皇岛）有限公司，持股 比例为100%。该子公司已取得秦皇岛市市场监督管理局经济技术开发区分局颁发的《营业执照》，注 册资本为伍佰万元整。康泰医学本次投资旨在推动公司业务高质量发展，完善产业布局，提高综合竞争 力。投资资金为自有资金，短期内不会对公司的财务状况和经营活动产生重大影响。 ...

证券代码：300869 证券简称：康泰医学 公告编号：2025-070 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于投资设立子公司并完成工商注册登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、投资概述 （一）基本情况 本次对外投资设立全资子公司不构成关联交易，也不构成《上市公司重大资 产重组管理办法》规定的重大资产重组。 二、子公司的基本情况 近日，上述子公司完成了工商注册登记手续，并取得了秦皇岛市市场监督管 理局经济技术开发区分局颁发的《营业执照》，基本信息登记如下： 企业名称：医电精测技术服务（秦皇岛）有限公司 统一社会信用代码：91130301MAEW3C959Q 根据康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）战略规划， 为推动公司业务高质量发展，完善公司产业布局，进一步提高综合竞争力，公司 出资人民币 500 万元设立全资子公司医电精测技术服务（秦皇岛）有限公司。公 司本次全部以自有资金出资，持股比例为 100%。 （二）审议情况 根据《深圳证券交易所创业板股票上市规则》和《康泰医学系 ...

9月18日，康泰医学（300869.SZ）股价高开低走，收盘下跌1.81%，总市值停留在67.66亿元。这一市场 表现背后，是一则牵动投资者神经的公告——公司重要股东王桂丽持股比例已降至10%的整数关口。 四年减持之路 根据9月17日公告，截至9月16日，王桂丽持有康泰医学股份降至40，180，326股，占公司总股本 10.00%，触及5%整数倍变动线。这场减持马拉松始于2021年8月，当时其持股比例高达14.70%。四年来 通过连续操作，王桂丽持股数量减少近1900万股，减持原因始终标注为"自身资金需求"。2021年8月至 今，王桂丽持股从14.70%降至10.00% 高管减持潮涌动 值得关注的是，减持并非王桂丽"独角戏"。公司董事兼高管杨志山、董事高瑞斌，以及付春元、寇国治 等五位高管同步推进减持计划，八位股东清一色标注"自身资金需求"。这场自2021年开启的高管减持 潮，在资本市场投下涟漪。 投资者的尖锐质疑 在9月15日业绩说明会上，投资者直指核心："为何高管一直在减持，是看不好公司发展吗？"这道出了 二级市场的普遍疑虑。尽管公司上半年交出了净利润1693.76万元、同比暴增107.39%的亮眼成绩单 ...

康泰医学系统（秦皇岛）股份有限公司 关于"康医转债"预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300869 证券简称：康泰医学 公告编号：2025-069 债券代码：123151 债券简称：康医转债 特别提示： 1、证券代码：300869，证券简称：康泰医学 2、债券代码：123151，债券简称：康医转债 3、当前转股价格：人民币 27.55 元/股 4、转股期限：2023 年 1 月 9 日至 2028 年 6 月 30 日 5、自 2025 年 9 月 6 日至 2025 年 9 月 19 日，康泰医学系统（秦皇岛）股份 有限公司（以下简称"公司"）股票已有 10 个交易日的收盘价低于"康医转债" 当期转股价格的 85%。根据《康泰医学系统（秦皇岛）股份有限公司创业板向不 特定对象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的 相关规定："在本次可转债存续期间，当公司股票在任意连续三十个交易日中至 少有十五个交易日的收盘价格低于当期转股价格的 85%时，公司董事会有权提出 转股价格向 ...

Core Viewpoint - Shareholder Wang Guili plans to reduce her stake in Kangtai Medical by a total of 18.9011 million shares, representing 4.70% of the company's total share capital, due to personal funding needs [1] Summary by Sections Shareholder Actions - Wang Guili will reduce her holdings from September 24, 2021, to September 16, 2025, bringing her ownership down to 10.00% after the reduction [1] - The planned reduction includes a maximum of 4 million shares through centralized bidding (1.00% of total share capital) and 8 million shares through block trading (1.99% of total share capital) within three months after the announcement [1] Company Governance - The equity change does not involve a change in the company's controlling shareholder or actual controller, and it will not affect the company's governance structure or ongoing operations [1]

证券代码：300869 证券简称：康泰医学 公告编号：2025-068 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 1、本次权益变动属于持股 5%以上股东王桂丽减持公司股份，不触及要约收购。 关于持股5%以上股东权益变动触及5%整数倍 暨披露简式权益变动报告书的提示性公告 持股5%以上股东王桂丽保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 2、本次权益变动不涉及公司控股股东及实际控制人，不会导致公司控股股东及 实际控制人发生变更，不会影响公司的治理结构和持续经营。 3、本次权益变动后，持股 5%以上股东王桂丽持有公司股份减少至 40,180,326 股，占公司目前总股本的 10.00%，触及 5%的整数倍。 特别提示： 注：1.表格中比例总数与分项数值之和不符的情况，为四舍五入原因造成。 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）于2021年8月24日 披露了《关于持股5%以上股东、部分董事、监事及高级管理人员减持股份的预披露 公告》（公告编号：2021-0 ...

康泰医学系统（秦皇岛）股份有限公司 简式权益变动报告书 信息披露义务人：王桂丽 住所及通讯地址：河北省秦皇岛市海港区**** 股份变动性质：股份减少、股份变动比例触及5%整数倍 签署日期：2025年9月17日 上市公司：康泰医学系统（秦皇岛）股份有限公司 上市地点：深圳证券交易所 股票简称：康泰医学 股票代码：300869 信息披露义务人声明 一、本报告书系根据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报告书》及相 关法律、法规和规范性文件编写。 第一节 释义 | 本报告书中，除非另有说明，下列简称具有以下含义： | | --- | | 信息披露义务人 | 指 | 王桂丽 | | --- | --- | --- | | 上市公司、康泰医学、公司 | 指 | 康泰医学系统（秦皇岛）股份有限公司 | | 报告书、本报告书 | 指 | 康泰医学系统（秦皇岛）股份有限公司简式权益变动 | | | | 报告书 | | 本次权益变动 | 指 | 2021年9月24日至2025年9月16日期间，信息披露义务人 | | | | 因股份减持，导致其在公司股份 ...

Core Viewpoint - 康泰医学 held an investor relations meeting on September 15, 2025, to discuss product development and market strategies, revealing significant insights into their operations and future plans [1] Group 1: Product Development - The "Embodied Motion Rehabilitation Intelligent Equipment" project, led by Hebei University of Technology in collaboration with Fudan University and Yanshan University, won the first prize in the 2024 Hebei Provincial Science and Technology Progress Award, indicating successful technology transfer into business applications [1] - The company is focusing on the development of mid-to-high-end products and medical devices to address product homogenization and meet changing market demands [1] - The company is actively working on the development of exoskeleton robot products and will disclose relevant information as per regulatory requirements [1] Group 2: Market Strategy - 康泰医学 is enhancing its domestic market presence through deep collaborations with leading e-commerce platforms to boost brand awareness and influence [1] - The company plans to expand its global market coverage by leveraging research and product advantages, targeting regions such as Southeast Asia, Africa, and South America, driven by the increasing demand for cost-effective medical devices due to global aging and home healthcare trends [1] Group 3: Financial Performance - The company's second-quarter profits were impacted by market conditions, seasonal sales, and increased R&D investments, prompting a focus on market promotion, product structure optimization, and cost control to enhance profitability [1] - Shareholder reductions were attributed to personal funding needs, with the company adhering to regulations and commitments while maintaining normal operations [1] Group 4: AI and Innovation - 康泰医学 is investing in AI technology, exploring its integration with medical devices, and focusing on innovations in patient monitoring through algorithm development, aiming to advance smart healthcare [1]

Group 1: Product Development and Innovation - The company has developed key technologies in "embodied motion rehabilitation intelligent equipment," which won the 2024 Hebei Provincial Science and Technology Progress Award [2] - Ongoing projects include medical endoscopes, in vitro diagnostic products, and dental consumables to meet changing market demands [3] - The company focuses on high-end products and has optimized existing products in ECG, blood pressure, and blood oxygen categories while actively developing new products [2] Group 2: Market Strategy and Expansion - The company is enhancing its domestic market presence through deep cooperation with leading e-commerce platforms to increase brand awareness [4] - Plans to expand into Southeast Asia, Africa, and South America are underway, targeting the growing demand for cost-effective medical devices in these regions [6] - The company aims to improve global market coverage and penetration through localized construction and cross-border e-commerce initiatives [6] Group 3: Financial Performance and Governance - The company's performance in the second quarter was not profitable, with profits primarily from the first quarter; management remains confident in future growth [7] - Shareholder reductions in holdings are attributed to personal financial needs and comply with legal regulations [7] - Recent changes in the supervisory board were part of normal governance optimization and did not involve any collective board incidents [4] Group 4: Technological Advancements - The company is actively investing in AI technology, focusing on integrating AI with medical devices and developing algorithms for patient monitoring [7] - Innovations include multi-mode temperature detection and pulse wave-based respiratory rate calculations, contributing to the advancement of smart healthcare [7]